News | June 07, 2022
NewAmsterdam Pharma shares new data from Phase 2b ROSE Study
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
To address the preventive & primary healthcare delivery gaps in India
Follows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategy
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases
An Integrated programme comprising GOQii device, Glucometer – Contour Plus+1 from Ascensia Diabetes Care India and personalised diabetes coaching
The demand for high-quality paediatric medicines has been growing rapidly in China as a result of the government’s support and policy measures
Shoreline has developed a proprietary methodology to create differentiated iNK cells for large-scale, "off-the-shelf" production
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
Subscribe To Our Newsletter & Stay Updated
